Neil Maruoka highlights encouraging prospects for AUPH lead asset in lupus nephritis after Analyst Day.
Elemer Piros reaffirms his bullish thesis on AUPH after a compelling R&D day mapping the next 24 months.
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares are rising nearly 4% in pre-market trading Friday, after the drug maker announced plans to expand its voclosoprin renal …
